Comparison in patients with type 2 diabetes of fibric acid versus HMG-CoA reductase inhibitor treatment of combined dyslipidemia

被引：0
|
作者：
McLaughlin, TL
Abbasi, F
Lamendola, CA
Leary, E
Reaven, GM
机构：
来源：
DIABETES | 2002年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2036
引用
收藏
页码：A495 / A496
页数：2
相关论文
共 50 条
  • [41] Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes
    Qin, J
    Zhang, ZL
    Liu, J
    Sun, L
    Hu, L
    Cooper, ME
    Cao, ZM
    KIDNEY INTERNATIONAL, 2003, 64 (02) : 565 - 571
  • [42] Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
    BakkerArkema, RG
    Davidson, MH
    Goldstein, RJ
    Davignon, J
    Isaacsohn, JL
    Weiss, SR
    Keilson, LM
    Brown, WV
    Miller, VT
    Shurzinske, LJ
    Black, DM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02): : 128 - 133
  • [43] Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
    BakkerArkema, RG
    Davidson, MH
    Goldstein, RJ
    Davignon, J
    Isaacsohn, JL
    Weiss, SR
    Keilson, LM
    Brown, WV
    Miller, VT
    Shurzinske, LJ
    Black, DM
    PERFUSION, 1996, 9 (05): : 163 - &
  • [44] LYTHOLITIC EFFECT OF SIMVASTATIN, AN HMG-COA REDUCTASE INHIBITOR, IN HYPERCHOLESTEROLEMIC GALLSTONE PATIENTS
    NERI, M
    SALVATORE, L
    SCHIAVONE, C
    MEZZETTI, A
    LATERZA, F
    CUCCURULLO, F
    GASTROENTEROLOGY, 1994, 106 (04) : A352 - A352
  • [45] The Effects of Combined Treatment with an HMG-CoA Reductase Inhibitor and PPARγ Agonist on the Activation of Rat Pancreatic Stellate Cells
    Lee, Beom Jae
    Lee, Hong Sik
    Kim, Chang Duck
    Jung, Sung Woo
    Seo, Yeon Seok
    Kim, Yong Sik
    Jeen, Yoon Tae
    Chun, Hoon Jai
    Um, Soon Ho
    Lee, Sang Woo
    Choi, Jai Hyun
    Ryu, Ho Sang
    GUT AND LIVER, 2012, 6 (02) : 262 - 269
  • [46] A 6-MONTH TRIAL OF SIMVASTATIN (HMG-COA REDUCTASE INHIBITOR) IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
    STEYN, K
    WEICH, HFH
    VERMAAK, WJH
    MARAIS, AD
    OMAR, MAK
    VANGELDER, AL
    FOURIE, J
    KOTZE, TJVW
    STANDER, I
    FIRTH, JC
    VANLATHEM, JM
    SOUTH AFRICAN MEDICAL JOURNAL, 1991, 79 (11): : 639 - 645
  • [47] FOCUS ON FLUVASTATIN - THE FIRST TOTALLY SYNTHETIC HMG-COA REDUCTASE INHIBITOR FOR TREATMENT OF HYPERCHOLESTEROLEMIA
    KELLICK, KA
    ELLIS, AK
    HOSPITAL FORMULARY, 1994, 29 (04): : 245 - 250
  • [48] Rosiglitazone in combination with an HMG CoA reductase inhibitor: Safety and effects on lipid profile in patients with type 2 diabetes
    Cohen, BR
    Kreider, M
    Biswas, N
    Brunzell, J
    Ratner, RE
    Freed, MI
    DIABETES, 2001, 50 : A451 - A451
  • [49] HMG-CoA Reductase Inhibitor (Statin) Prescribing for Ischemic Stroke Patients at Hospital Discharge
    Albright, Karen
    Vahidy, Farhaan
    Moore, Makenna
    Samai, Alyana
    Schluter, Laurie
    Martin-Schild, Sheryl
    NEUROLOGY, 2016, 86
  • [50] The Effect of HMG-CoA Reductase Inhibitor on Insulin Resistance in Patients Undergoing Peritoneal Dialysis
    Doh, Fa Mee
    Chang, Tae-Ik
    Koo, Hyang Mo
    Lee, Mi Jung
    Shin, Dong Ho
    Kim, Chan Ho
    Ko, Kwang Il
    Oh, Hyung Jung
    Yoo, Tae-Hyun
    Kang, Shin-Wook
    Han, Dae-Suk
    Han, Seung Hyeok
    CARDIOVASCULAR DRUGS AND THERAPY, 2012, 26 (06) : 501 - 509
12345